Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells

Conclusions:
Our results suggest that olaparib, a PARP inhibitor, is effective on certain endometrial cancer cell lines. Inactivation of PTEN might not affect the DNA repair function. Predictive biomarkers are warranted to utilize olaparib in endometrial cancer.

Source: Epidemiologic Perspectives and Innovations - March 13, 2014 Category: Epidemiology Authors: Aki MiyasakaKatsutoshi OdaYuji IkedaOsamu Wada-HiraikeTomoko KashiyamaAtsushi EnomotoNoriko HosoyaTakahiro KosoTomohiko FukudaKanako InabaKenbun SoneYuriko UeharaReiko KurikawaKazunori NagasakaYoko MatsumotoTakahide ArimotoShunsuke NakagawaHiroyuki Kuramo Source Type: research